CARR EDWARD has filed 15 insider transactions across 1 company since January 2024.
Most recent transaction: a option exercise of 10000 shares of Dianthus Therapeutics, Inc. /DE/ ($DNTH) on March 12, 2026.
Activity breakdown: 0 open-market purchases and 5 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | M | Stock Option (Right to Buy) | 10000 | $0.00 | 50,000.0000 | 42,876,015 | 16.67% | 0.02% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | S | Common Stock | 200 | $83.38 | 300.0000 | 42,876,015 | 40.00% | 0.00% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | S | Common Stock | 300 | $85.53 | 0.0000 | 42,876,015 | 100.00% | 0.00% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | M | Stock Option (Right to Buy) | 16182 | $0.00 | 63,818.0000 | 42,876,015 | 20.23% | 0.04% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | M | Stock Option (Right to Buy) | 17500 | $0.00 | 42,500.0000 | 42,876,015 | 29.17% | 0.04% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | M | Common Stock | 16182 | $17.88 | 16,182.0000 | 42,876,015 | 9999.99% | 0.04% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | M | Common Stock | 17500 | $22.07 | 33,682.0000 | 42,876,015 | 108.14% | 0.04% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | M | Common Stock | 10000 | $21.77 | 43,682.0000 | 42,876,015 | 29.69% | 0.02% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | S | Common Stock | 15852 | $80.71 | 27,830.0000 | 42,876,015 | 36.29% | 0.04% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | S | Common Stock | 23465 | $81.75 | 4,365.0000 | 42,876,015 | 84.32% | 0.05% |
| March 12, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | S | Common Stock | 3865 | $82.66 | 500.0000 | 42,876,015 | 88.55% | 0.01% |
| Feb. 3, 2026 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 42,876,015 | 9999.99% | 0.13% |
| Feb. 3, 2025 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| May 23, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | A | Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 24, 2024 | Dianthus Therapeutics, Inc. /DE/ | $DNTH | CARR EDWARD | CHIEF ACCOUNTING OFFICER | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 0 | 9999.99% | 0.00% |